Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Cabergoline and Exemestane Interaction: Synergistic | Peptide Database

Compound Profiles Cabergoline Dopamine Agonist | Prolactin Management Cabergoline exerts its effects by acting as a potent agonist at dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. Prolactin secretion is tonically inhibited by hypot

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Cabergoline

Dopamine Agonist | Prolactin Management

Cabergoline exerts its effects by acting as a potent agonist at dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. Prolactin secretion is tonically inhibited by hypothalamic dopamine acting on these D2 receptors, and cabergoline mimics this inhibitory signal with high affinity and prolonged duration.

Exemestane

Steroidal Aromatase Inhibitor | Irreversible Estrogen Control

Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Cabergoline with Exemestane?

Yes, Cabergoline and Exemestane can generally be taken together. Exemestane supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.

Is Cabergoline and Exemestane safe together?

Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: pct agent. Monitor accordingly.

What are the interactions between Cabergoline and Exemestane?

Exemestane supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life. This assessment has 65% confidence and is inferred from pharmacological mechanism analysis.

How should I time Cabergoline and Exemestane?

Cabergoline has a half-life of ~63-69 hours and Exemestane has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Standard Selank approved in Russia for GAD; NA-Selank Amidate offers enhanced delivery. Modulates stress response through GABA and serotonin systems without sedation. Improves mood through serotonin metabolism activation. Increases memory trace stability for up to 30 days in animal studies. BDNF elevation supports learning and neuroplasticity. BDNF increase reduces effects of neurological injury. Based on tuftsin structure, retains immunomodulatory properties.

Source: peptide-db.com ↗

Research Indications

First-line pharmacotherapy for lifelong and acquired premature ejaculation. Clinically proven to increase intravaginal ejaculatory latency time (IELT), improve perceived control over ejaculation, and reduce personal distress related to PE. Improved ejaculatory control leads to greater sexual satisfaction for both the individual and their partner, as measured by validated patient-reported outcome instruments in clinical trials.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Potential benefits

How long after stopping EPO do benefits disappear?

EPO's effects begin diminishing once injections stop as red blood cells have a natural 120-day lifespan. Hemoglobin returns toward baseline within 2-3 weeks of discontinuation. Most performance benefits fade quickly, making continued use necessary for sustained effects, which is why athletes faced testing challenges in endurance sports.

Source: peptide-db.com ↗
Side effects

Common Side Effects

Morning drowsiness or grogginess (more common at the 6 mg dose; uncommon at 3 mg) Dry mouth (mild at ultra-low doses, much less than at antidepressant doses) Nausea Upper respiratory tract infection (observed in clinical trials at rates similar to placebo)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides